Arcus Capital Partners LLC grew its holdings in shares of JPMorgan Chase & Co. (NYSE:JPM) by 31.7% during the fourth quarter, ...

Arcus Biosciences Inc. (NYSE: RCUS) shares are trading lower Tuesday after the company announced a $150 million common stock ...

Research analysts at Wedbush issued their FY2029 EPS estimates for shares of Arcus Biosciences in a note issued to investors ...

Casdatifan’s progression-free survival benefits could help differentiate it from Merck’s Welireg in the kidney cancer arena, ...

The news comes on the heels of promising Phase I/Ib data, which point to the potential of casdatifan as a more effective ...

Gilead Sciences has defied analysts’ expectations by passing on its chance to license Arcus Biosciences’ potential rival to Merck & Co.’s kidney cancer drug Welireg.

One thing we could say about the analysts on Arcus Biosciences, Inc. (NYSE:RCUS) - they aren't optimistic, having just made a major negative revision to their near-term (statutory) forecasts for the ...

Arcus Biosciences (NYSE:RCUS) shares dipped 4% after the company priced a stock offering to raise approximately $150 million. The offering consists of 13,636,364 shares of common stock issued at ...

H.C. Wainwright lowered the firm’s price target on Arcus Biosciences (RCUS) to $18 from $20 and keeps a Buy rating on the shares after the ...

Arcus Biosciences shares were down 14%, to $11.33, after the company priced a $150 million stock offering. Shares of the biopharmaceutical company hit their 52-week low of $10.65 earlier in the ...

Arcus Biosciences (RCUS) announced that Gilead’s (GILD) time-limited exclusive option rights to casdatifan have expired. In addition, Arcus has ...